Life Science Business of Merck KGaA, Darmstadt, Germany Receives Patent for CRISPR Technology in China
Merck KGaA, Darmstadt, Germany today announced that the Chinese Patent Office has issued a notice granting a patent application for the company’s CRISPR technology used in a genomic-integration method for...
- Patent in China covers integration of an external DNA sequence into the chromosome of eukaryotic cells
- Company to license CRISPR-related patents to interested parties, supports genome-editing research under ethical and legal standards
- Foundational CRISPR patents now granted in seven markets, including Canada and Europe
Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, today announced that the Chinese Patent Office has issued a notice granting a patent application for the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells.
“Including China, we have received seven crucial patents for our foundational CRISPR technology, which defines an exciting new path for medical research and treatments for some of the toughest medical conditions, including cancer, hereditary and rare diseases,” said Udit Batra, Member of the Executive Board and CEO, Life Science business of Merck KGaA, Darmstadt, Germany. “As a genome-editing leader, we are actively licensing our integration patents for therapeutic use, basic science research and agricultural biotechnology.”
The Life Science business of Merck KGaA, Darmstadt, Germany, which has a 13-year history in the genome-editing field, has related patent filings for its insertion CRISPR method in the U.S., Brazil, India and Japan. The company already has had similar key patents granted in Australia, Canada, Europe, Israel, Singapore and South Korea.
This forthcoming patent in China covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence — a method important for creating disease models and gene therapy. Additionally, the method can be used to insert transgenes that label endogenous proteins for visual tracking within cells.
CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for a variety of medical conditions. CRISPR applications are far-ranging - from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.
As a company that has been highly involved in genome-editing innovation, Merck KGaA, Darmstadt, Germany recognizes that genome-editing has resulted in major positive advancements in biological research and medicine. At the same time, the growing potential of gene-editing technologies has opened scientific, legal and societal concerns. As both a user and supplier of gene-editing technology, the businesses of Merck KGaA, Darmstadt, Germany support research with genome editing under careful consideration of ethical and legal standards. The company has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational position taking into account scientific and societal issues while not blocking any promising therapeutic approaches for use in research and applications.
The Life Science business of Merck KGaA, Darmstadt, Germany has made significant contributions to the genome-editing field. It was the first to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world. It was also the first to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.
For more information on the company’s work in the genome-editing field, visit https://www.emdgroup.com/en/stories/350-anniversary-its-all-in-the-genes.html.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive ...
Merck KGaA, Darmstadt, Germany announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO®